(Total Views: 535)
Posted On: 10/12/2021 2:47:48 PM
Post# of 154090
Re: onestepahead #107435
Onestepahead,
I believe the data Cytodyn received back from the FDA is limited to the sequences for the tNBC patients.
Work not done or not done appropriately for other trials will hinder progress in a number of fronts.
Sequencing to support BTD in tNBC is valuable, but only a (small?) part of the work for which Amarex has been paid and appears not to have completed appropriately.
I believe the data Cytodyn received back from the FDA is limited to the sequences for the tNBC patients.
Work not done or not done appropriately for other trials will hinder progress in a number of fronts.
Sequencing to support BTD in tNBC is valuable, but only a (small?) part of the work for which Amarex has been paid and appears not to have completed appropriately.
(7)
(0)
